Hidradenitis Suppurativa Market Outlook, 2032 | Insights Into the Evolving Market Dynamics, Growth Opportunities, Epidemiology Trends, Emerging Therapies, Treatment Algorithm, and Key Companies

January 11 19:16 2023
Hidradenitis Suppurativa Market Outlook, 2032 | Insights Into the Evolving Market Dynamics, Growth Opportunities, Epidemiology Trends, Emerging Therapies, Treatment Algorithm, and Key Companies
Delveinsight Business Research LLP
As per DelveInsight, the Hidradenitis Suppurativa market size is anticipated to grow in the coming years owing to the increasing prevalent pool, the increase in disease awareness, the rise in healthcare spending across the world, and the expected entries of emerging therapies like secukinumab, IFX-1, bermekimab (MABp1), bimekizumab, Avacopan, and others.

Several major pharmaceutical and biotech giants are thoroughly working toward the development of new treatment therapies for Hidradenitis Suppurativa in order to provide better relief for the symptoms and hence improve the Quality of life (QoL) of patients with HS.

DelveInsight’s “Hidradenitis Suppurativa Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Hidradenitis Suppurativa market size, share, and trends in the seven major market (7MM) (i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan).

The Hidradenitis Suppurativa market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Hidradenitis Suppurativa Market

Hidradenitis Suppurativa: An Overview

According to the NORD, Hidradenitis Suppurativa is a chronic condition characterized by swollen, painful lesions occurring in the armpit, groin, and several other body parts. It is a painful and long-term skin condition causing abscesses and scarring on the skin. Affected patients may present with acute abscesses, but the condition often progresses to a chronic state with persistent pain, sinus tract fistula formation, and scarring. 

There is no cure for Hidradenitis Suppurativa, early diagnosis and treatment help prevent the disease from getting worse and forming additional scars, and the current treatment approaches depend on the severity and clinical staging of the disease. Several lifestyle modifications are recommended, such as smoking cessation, weight loss, and stress management, but there is little evidence regarding their efficacy.

In terms of pharmacological treatment market options, therapies available in the market include topical and systemic antibiotics, corticosteroids, hormonal therapy, systemic retinoid, zinc supplements, and immunosuppressive agents, including biologics (HUMIRA, Infliximab). Other pharmacological therapies like birth control pills (to address the hormonal cause of HS) can also be used.

Hidradenitis Suppurativa Market Key Facts

  • The total market size of Hidradenitis Suppurativa in the US was USD 899 million in 2021 and is projected to grow during the forecast period (2022-2032).

  • Among the EU-5 countries, Germany has the maximum revenue share in 2021, while Spain has the lowest market share.

  • The market size of Hidradenitis Suppurativa in Japan was USD 13 million in 2021.

  • The total market size of Hidradenitis Suppurativa in the United States is expected to increase with a CAGR of 11% during the study period (2019–2032).

  • The total diagnosed prevalent population of Hidradenitis Suppurativa in the 7MM was found to be 1,239,000+ in 2021, and the cases are projected to increase during the forecast period.

  • The total diagnosed prevalent population of Hidradenitis Suppurativa in the United States was 572,000+ in 2021. 

  • Among the EU-5 countries, Germany accounted for the highest number of Hidradenitis Suppurativa cases, whereas Spain accounted for the lowest number of cases in 2021.

  • In Japan, the total diagnosed prevalent population of Hidradenitis Suppurativa was 89,000+ in 2021 and is anticipated to rise during the forecast period.

  • Some of the leading companies in the Hidradenitis Suppurativa therapeutics market include Inflarx, Novartis Pharmaceuticals, Incyte Corporation, UCB Biopharma, Janssen Pharmaceuticals, Novartis Pharmaceuticals, Amgen, Chemocentryx, Priovant Therapeutics, Pfizer, Anaptysbio, Abbvie, Acelyrin, Aclaris Therapeutics, Boehringer Ingelheim, Eli Lilly, Moonlake Immunotherapeutics, Aristea Therapeutics, and others.

Hidradenitis Suppurativa Market

The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Hidradenitis Suppurativa market size by analyzing the impact of current and emerging pipeline therapies. It also provides a thorough assessment of the market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.

The report gives complete detail of the Hidradenitis Suppurativa market trend for each marketed drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MoA), Route of Administration (RoA), molecule types, competition with other therapies, brand value, and their impact on the market.

Hidradenitis Suppurativa Epidemiology Assessment 

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pool, future trends, and and views of key opinion leaders. 

The Report Covers the Hidradenitis Suppurativa Epidemiology, Segmented by –

  • Total Prevalent Pool of Hidradenitis Suppurativa (2019–2032)

  • Gender-specific Prevalent Pool of Hidradenitis Suppurativa (2019–2032) 

  • Age-specific Prevalent Pool of Hidradenitis Suppurativa (2019–2032)

  • Stage-specific Prevalent Pool of Hidradenitis Suppurativa (2019–2032)

  • Diagnosed Pool of Hidradenitis Suppurativa (2019–2032)

  • Treated moderate to severe Prevalent Pool of Hidradenitis Suppurativa (2019–2032)

Hidradenitis Suppurativa Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Hidradenitis Suppurativa market or expected to get launched during the study period. The analysis covers the Hidradenitis Suppurativa market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Hidradenitis Suppurativa Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Learn How Hidradenitis Suppurativa Market Will Evolve by 2032 @ 

https://www.delveinsight.com/sample-request/hidradenitis-suppurativa-market

Some of the Leading Companies in the Hidradenitis Suppurativa Therapeutics Market Include:

  • Inflarx

  • Novartis Pharmaceuticals

  • Incyte Corporation

  • UCB Biopharma Sprl

  • Janssen Pharmaceuticals

  • Novartis Pharmaceuticals

  • Amgen

  • Chemocentryx

  • Priovant Therapeutics

  • Pfizer

  • Anaptysbio

  • Abbvie

  • Acelyrin

  • Aclaris Therapeutics

  • Boehringer Ingelheim

  • Eli Lilly

  • Moonlake Immunotherapeutics

  • Aristea Therapeutics

And Many Others

Hidradenitis Suppurativa Drugs Covered in the Report Include:

  • COSENTYX (secukinumab): Novartis Pharmaceuticals

  • SKYRIZI (risankizumab): AbbVie

  • BIMZELX (bimekizumab): UCB Biopharma SPRL

  • Bermekimab: Janssen Pharmaceuticals

  • OTEZLA (Apremilast): Amgen

  • IFX-1: InflaRx

  • Brepocitinib: Priovant Therapeutics

  • Zunsemetinib (CDD-450): Aclaris Therapeutics

And Many More 

Further Emerging Drugs & Key Companies are Covered in the Report. Download the Sample PDF to Learn More:

https://www.delveinsight.com/sample-request/hidradenitis-suppurativa-market

Table of Content (TOC)

1. Key Insights

2. Executive Summary 

3. Hidradenitis Suppurativa Competitive Intelligence Analysis

4. Hidradenitis Suppurativa Market Overview at a Glance

5. Hidradenitis Suppurativa Disease Background and Overview

6. Hidradenitis Suppurativa Patient Journey

7. Hidradenitis Suppurativa Epidemiology and Patient Population (In the US, EU5, and Japan)

8. Hidradenitis Suppurativa Treatment Algorithm, Current Treatment, and Medical Practices

9. Hidradenitis Suppurativa Unmet Needs

10. Key Endpoints of Hidradenitis Suppurativa Treatment

11. Hidradenitis Suppurativa Marketed Products

12. Hidradenitis Suppurativa Emerging Drugs and Latest Therapeutic Advances

13. Hidradenitis Suppurativa Seven Major Market Analysis

14. Attribute Analysis

15. Hidradenitis Suppurativa Market Outlook (In US, EU5, and Japan)

16. Hidradenitis Suppurativa Access and Reimbursement Overview

17. KOL Views on the Hidradenitis Suppurativa Market

18. Hidradenitis Suppurativa Market Drivers

19. Hidradenitis Suppurativa Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

Download the Sample PDF to Explore the Key Offerings of the Report: https://www.delveinsight.com/sample-request/hidradenitis-suppurativa-market

Other Trending Healthcare Reports By DelveInsight

Hidradenitis Suppurativa Pipeline Insight

Hidradenitis Suppurativa – Pipeline Insight, 2023” report provides comprehensive insights about 24+ companies and 24+ drugs in the Hidradenitis Suppurativa pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products by stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

  Categories: